Literature DB >> 23816390

Latent papillomavirus infections and their regulation.

John Doorbar1.   

Abstract

Model systems show that papillomavirus DNA can persist after lesion-regression, and be maintained in a subset of epithelial basal cells. These are very likely long-lived 'stem-cells' or 'stem-like cells', with latency arising via at least two distinct mechanisms. The first involves low-titre virus infection and the retention of viral DNA at levels that are too low to allow life-cycle completion. The second involves lesion-formation, and clearance by the adaptive immune system, followed by persistence with low-level viral gene expression, and possible reactivation upon immune depletion. Mechanical irritation, inflammation and other extracellular influences affect viral copy number in the latently infected cell, and may predispose to lesion-reappearance. Reactivation may account for the recurrence of 'apparently cleared' cervical lesions caused by high-risk types, the appearance of Beta HPV-lesions following immunosuppression, and the development of recurrent respiratory papillomatosis in afflicted children. Crown
Copyright © 2013. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23816390     DOI: 10.1016/j.coviro.2013.06.003

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  33 in total

Review 1.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

Review 2.  Viruses and human cancers: a long road of discovery of molecular paradigms.

Authors:  Martyn K White; Joseph S Pagano; Kamel Khalili
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

4.  Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model.

Authors:  Jiafen Hu; Lynn R Budgeon; Nancy M Cladel; Karla Balogh; Roland Myers; Timothy K Cooper; Neil D Christensen
Journal:  J Gen Virol       Date:  2015-12       Impact factor: 3.891

5.  Prevalence of tonsillar human papillomavirus infections in Denmark.

Authors:  M Rusan; T E Klug; J J Henriksen; J H Bonde; K Fuursted; T Ovesen
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08-12       Impact factor: 2.503

6.  Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.

Authors:  Ricardo Rosales; Mario López-Contreras; Carlos Rosales; Jose-Roberto Magallanes-Molina; Roberto Gonzalez-Vergara; Jose Martin Arroyo-Cazarez; Antonio Ricardez-Arenas; Armando Del Follo-Valencia; Santiago Padilla-Arriaga; Miriam Veronica Guerrero; Miguel Angel Pirez; Claudia Arellano-Fiore; Freddy Villarreal
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

Review 7.  DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward.

Authors:  Nicholas D Weber; Martine Aubert; Chung H Dang; Daniel Stone; Keith R Jerome
Journal:  Virology       Date:  2014-01-31       Impact factor: 3.616

Review 8.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant.

Authors:  Jessica P Hwang; Sairah Ahmed; Ella J Ariza-Heredia; Zhigang Duan; Hui Zhao; Kathleen M Schmeler; Lois Ramondetta; Susan L Parker; Maria E Suarez-Almazor; Alessandra Ferrajoli; Ya-Chen Tina Shih; Sharon H Giordano; Elizabeth Y Chiao
Journal:  Biol Blood Marrow Transplant       Date:  2018-02-09       Impact factor: 5.742

Review 10.  Recent advances in preclinical model systems for papillomaviruses.

Authors:  Neil D Christensen; Lynn R Budgeon; Nancy M Cladel; Jiafen Hu
Journal:  Virus Res       Date:  2016-12-09       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.